PEGylated Silk Nanoparticles for Anticancer Drug Delivery

Thidarat Wongpinyochit, Petra Uhlmann, Andrew Urquhart, F. Philipp Seib

    Research output: Contribution to journalJournal articleResearchpeer-review


    Silk has a robust clinical track record and is emerging as a promising biopolymer for drug delivery, including its use as nanomedicine. However, silk-based nanomedicines still require further refinements for full exploitation of their potential; the application of “stealth” design principals is especially necessary to support their evolution. The aim of this study was to develop and examine the potential of PEGylated silk nanoparticles as an anticancer drug delivery system. We first generated B. mori derived silk nanoparticles by driving β-sheet assembly (size 104 ± 1.7 nm, zeta potential −56 ± 5.6 mV) using nanoprecipitation. We then surface grafted polyethylene glycol (PEG) to the fabricated silk nanoparticles and verified the aqueous stability and morphology of the resulting PEGylated silk nanoparticles. We assessed the drug loading and release behavior of these nanoparticles using clinically established and emerging anticancer drugs. Overall, PEGylated silk nanoparticles showed high encapsulation efficiency (>93%) and a pH-dependent release over 14 days. Finally, we demonstrated significant cytotoxicity of drug loaded silk nanoparticles applied as single and combination nanomedicines to human breast cancer cells. In conclusion, these results, taken together with prior silk nanoparticle data, support a viable future for silk-based nanomedicines.
    Original languageEnglish
    Issue number11
    Pages (from-to)3712-3722
    Publication statusPublished - 2015


    Dive into the research topics of 'PEGylated Silk Nanoparticles for Anticancer Drug Delivery'. Together they form a unique fingerprint.

    Cite this